AccuScan Shows MRD Data at AACR 2026 ↗
AccuScan Sciences announced interim data presented at the AACR Annual Meeting 2026 on its ultrasensitive whole-genome-sequencing-based ctDNA assay for postoperative MRD detection in colorectal cancer. The study evaluated 291 patients with Stage II–III disease and was conducted with Aarhus University researchers and Danish cancer centers.